JERUSALEM, Feb. 14 (Xinhua) -- An international team of researchers has developed a new technology to predict cancer patients' response to immunotherapy, the Israel Institute of Technology (Technion) said in a statement on Wednesday.
The Technion researchers and other researchers from Israel, the United States and Germany discovered that a specific type of neutrophils in the bloodstream acts directly on the immune system and stimulates them to target the tumor, and their presence in the tumor prompts greater sensitivity to immunotherapy treatment.
